EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

IDEXX Laboratories, Inc. (I1DX34) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of IDEXX Laboratories, Inc. BRL 393, price BRL 538, upside -27.0%, quality 84 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · Home US

IL Some data Oct 3, 2026

IDEXX Laboratories, Inc.

I1DX34 · SA

Great Company, Expensive PriceQuality growthHigh Quality, but the stock trades above estimated Fair Value.

!Fair value R$392.88 · Overvalued (−27.0%)
✓Quality 84/100
✓Healthy Growth (revenue 3y +8.5 %/yr)
✓Highly profitable · 24.6% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (7/10)
✓Wide moat 92/100
!Insider activity 40/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 27 out of 100
Watch IDEXX Laboratories, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$813.60 R$336.60 Fair Value R$392.88 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range R$336.60 – R$813.60 · fair‑value band R$250.66 – R$589.42 · the R$538.10 price screens above the R$392.88 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow IDEXX Laboratories in your weekly email

Every Wednesday you see whether IDEXX Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Show more

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Stock analysis

IDEXX Laboratories, Inc. (I1DX34) currently trades at R$538.10, while our model-based Fair Value estimate is R$392.88, 27.0% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of R$273.66 per share, and 0 of the 24 models we run sit above the R$538.10 price.

Bear case: the Economic Profit group reads lowest at R$92.22, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: R$250.66 (bear) to R$589.42 (bull), the price of R$538.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 84/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

IDEXX Laboratories, Inc. reported revenue of $4.3B in FY2025 versus $3.2B in FY2021, a compound +7.6%/yr. Reported net income was $1.1B in FY2025, compounding +9.2%/yr from FY2021.

Key figures

Market cap R$227B (≈ $43.6B) · P/E ratio 38.2 · P/S ratio 9.41 · EPS (TTM) R$14.07 · Net margin 24.6% · Return on equity 72.9% · Return on assets (EBIT) 35.9% · Operating margin 31.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −27%, I1DX34 screens richer than that median.

Fair Value models

Bear R$250.66 Fair Value R$392.88 Bull R$589.42
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$10.64 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$162.03 R$267.77 R$436.93 75
Growth DCF R$163.44 R$266.82 R$431.48 74
Owner Earnings R$165.62 R$273.66 R$446.51 72
All 24 models by family
DCF Models
FCF DCF R$162.03 R$267.77 R$436.93 75
Owner Earnings R$165.62 R$273.66 R$446.51 72
5Y Revenue Exit R$129.55 R$209.15 R$311.96 69
5Y EBITDA Exit R$177.87 R$302.77 R$452.19 71
5Y P/E Exit R$191.11 R$328.41 R$477.23 67
10Y Revenue Exit R$135.70 R$212.58 R$319.22 63
10Y EBITDA Exit R$170.74 R$278.83 R$429.83 64
10Y P/E Exit R$179.30 R$296.97 R$449.58 60
Earnings-Based
Graham-Dodd R$95.39 R$348.39 R$470.18 61
Lynch FV R$82.98 R$118.54 R$154.10 58
PEG = 1.0 R$82.98 R$118.54 R$154.10 55
EPV R$132.91 R$155.49 R$175.25 71
Multiples
P/E Multiple R$231.46 R$308.62 R$385.77 63
P/S Multiple R$149.58 R$199.44 R$249.30 58
P/B Multiple R$71.74 R$95.65 R$119.57 55
EV/EBIT R$227.02 R$303.55 R$380.08 66
EV/EBITDA R$206.69 R$276.44 R$346.20 67
EV/Revenue R$117.09 R$168.37 R$219.66 53
Asset-Based
NCAV (Graham) R$10.63 R$14.24 R$21.26 54
Growth DCF
Growth DCF R$163.44 R$266.82 R$431.48 74
Rev-Margin DCF R$129.55 R$209.17 R$305.06 69
Economic Profit
Residual Income R$70.15 R$92.22 R$185.86 63
ROIC Compounder R$140.65 R$174.02 R$210.13 69
Growth Earnings
Growth-Adj P/E R$160.76 R$229.65 R$298.55 65

Open the full fair value analysis →

Notify me when I1DX34 reaches fair value

Put I1DX34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 84/100

Of which business quality 81 · Market factors (momentum, volatility) 27

Profitability 99
Margins and returns on capital today
Quality Growth 76
Are margins and returns improving?
Cashflow 80
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 53
Disciplined investing over empire-building
Low Volatility 46
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 87/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.6%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 32%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.5% a year for the price and +5.3% for the forecasts.
Forecast 2026 (sales)+9.4%
Forecast 2027 (sales)+8.6%
Projected 2028 (sales)+7.8%
Projected 2029 (sales)+7.0%
Projected 2030 (sales)+6.2%

I1DX34 screens overvalued: fair value 27% below the price. Compare with Thermo Fisher Scientific Inc →

Compare IDEXX Laboratories, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 136 stocks

Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 84 · Top 25%
Fair Value upside −4.2% · Above median
Profitability
Return on equity (TTM) 72.9% · Top 25%
Return on assets 26.5% · Top 25%
Net margin (TTM) 24.6% · Top 25%
Operating margin (TTM) 31.8% · Top 25%
Growth and dividend
Revenue growth 14.3% · Above median
Balance sheet
Debt / equity 0.23× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 38.2× · Pricier than median
PEG 3.57× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 0
FUTURE (revenue growth)72 · sector 28
PAST (return on equity)100 · sector 10
HEALTH (low debt)88 · sector 93
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%
Quest Diagnostics Incorporated DGX $237.62 $171.69 −28%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

IDEXX Laboratories, Inc. · Fair Value
R$392.88 −27%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "IDEXX Laboratories, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/I1DX34

Frequently asked questions

Is IDEXX Laboratories, Inc. (I1DX34) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of R$392.88 versus a price of R$538.10, about −27% upside (overvalued).
What is the fair value of I1DX34?
Our model-based fair value for IDEXX Laboratories, Inc. is R$392.88 (as of Oct 3, 2026), built from audited fundamentals. The current price: R$538.10.
What is the quality score of I1DX34?
IDEXX Laboratories, Inc. has a Quality Score of 84/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IDEXX Laboratories, Inc. (I1DX34)?
Our model-based price target is the fair value of R$392.88 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario R$250.66, optimistic scenario R$589.42. It is a calculation from audited fundamentals, not an analyst target.
What is the IDEXX Laboratories, Inc. stock forecast for 2026?
Our models put fair value at R$392.88, about −27% upside versus a price of R$538.10 (overvalued). Cautious scenario R$250.66, optimistic scenario R$589.42. The calculation is refreshed regularly with new filings.
What is the revenue of IDEXX Laboratories, Inc. (I1DX34)?
IDEXX Laboratories, Inc. reported trailing-twelve-month revenue of about $4.4B (latest available figure, as of Oct 3, 2026).
What growth is priced into IDEXX Laboratories, Inc. (I1DX34)?
For today's price to be fair in a discounted-cash-flow model, IDEXX Laboratories, Inc. would have to grow free cash flow by +1.9 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +7.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of I1DX34 use?
Our models discount IDEXX Laboratories, Inc. at 13.9 %: a base by market capitalisation (large), damped by beta 1.55, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For IDEXX Laboratories, Inc. that is +1.9 % per year a year over ten years, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has IDEXX Laboratories, Inc. (I1DX34) delivered so far?
Over the past 4 years revenue at IDEXX Laboratories, Inc. grew +7.6 % a year. The price currently implies +1.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of IDEXX Laboratories, Inc. (I1DX34) growing?
The median revenue growth in the sector is +2.1 % a year. That is the yardstick for the growth priced into IDEXX Laboratories, Inc. (+1.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of IDEXX Laboratories, Inc. (I1DX34)?
The free-cash-flow yield on the price is 12.71 %: that much free cash flow IDEXX Laboratories, Inc. produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of IDEXX Laboratories, Inc. (I1DX34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IDEXX Laboratories, Inc. it is R$392.88 per share (as of Oct 3, 2026), against a price of R$538.10. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is IDEXX Laboratories, Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, I1DX34 trades above its calculated fair value: price R$538.10, fair value R$392.88, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of I1DX34?
No. The price is what the market pays today (R$538.10); the fair value is what the company's own numbers justify (R$392.88). For IDEXX Laboratories, Inc. the two are R$145.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is IDEXX Laboratories, Inc. worth?
The market values IDEXX Laboratories, Inc. at about R$227B (market capitalisation, as of Oct 3, 2026). Per share that is R$538.10; our models calculate a fair value of R$392.88 per share.
What do the bullish and bearish scenarios say about I1DX34?
Our models span a range for IDEXX Laboratories, Inc.: cautious scenario R$250.66, base R$392.88, optimistic R$589.42 per share (as of Oct 3, 2026, price R$538.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of I1DX34?
IDEXX Laboratories, Inc. trades at a price-to-earnings ratio of 38.2 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$392.88 is built from several models across several years. Other multiples: PEG 3.6.
What is the PEG ratio of I1DX34?
The PEG ratio of IDEXX Laboratories, Inc. is 3.57 (P/E divided by earnings growth, as of Oct 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of IDEXX Laboratories, Inc. (I1DX34)?
Balance-sheet figures for IDEXX Laboratories, Inc. (as of Oct 3, 2026): return on equity 72.9%, debt of 0.23 per unit of equity. They feed the Quality Score of 84/100, which measures business quality independently of the share price.
How far is I1DX34 from its 52-week high?
IDEXX Laboratories, Inc. trades at R$538.10, about 34% below its 52-week high of R$813.60 and 3% above the low of R$521.50 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$392.88 is for.
Which stocks are comparable to IDEXX Laboratories, Inc.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IDEXX Laboratories, Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price R$538.10, calculated fair value R$392.88 (−27%), Quality Score 84/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of I1DX34 calculated?
We run IDEXX Laboratories, Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$392.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. IDEXX Laboratories, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IDEXX Laboratories, Inc. (I1DX34)?
The closing price on Oct 1, 2026 was R$538.10. Our model-based fair value is R$392.88, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IDEXX Laboratories, Inc. right now?
A high-quality business (quality 84/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (R$250.66 to R$589.42) leaves room in how you read the outcome.

Key figures of IDEXX Laboratories, Inc.

How large is the market capitalisation of IDEXX Laboratories, Inc. (I1DX34)?
The market capitalisation of IDEXX Laboratories, Inc. is R$227B (≈ $43.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IDEXX Laboratories, Inc. (I1DX34)?
The price-to-sales ratio of IDEXX Laboratories, Inc. is 9.41 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IDEXX Laboratories, Inc. (I1DX34)?
Earnings per share at IDEXX Laboratories, Inc. are R$14.07 (price ÷ EPS = P/E 38.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of IDEXX Laboratories, Inc. (I1DX34)?
The net margin of IDEXX Laboratories, Inc. is 24.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IDEXX Laboratories, Inc. (I1DX34)?
The return on equity (ROE) of IDEXX Laboratories, Inc. is 72.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IDEXX Laboratories, Inc. (I1DX34)?
On an EBIT basis the return on assets of IDEXX Laboratories, Inc. is 35.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IDEXX Laboratories, Inc. (I1DX34)?
The operating margin of IDEXX Laboratories, Inc. is 31.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IDEXX Laboratories, Inc. (I1DX34)?
Revenue at IDEXX Laboratories, Inc. is growing +14.3% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at IDEXX Laboratories, Inc. (I1DX34)?
Earnings per share at IDEXX Laboratories, Inc. are growing +17.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does IDEXX Laboratories, Inc. (I1DX34) carry?
The net debt of IDEXX Laboratories, Inc. is $668M (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch IDEXX Laboratories, Inc. in the live analysis

One click puts IDEXX Laboratories, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.